MAP2 scoring and neoplasm grading (low vs. high-grade) comparison: Most high-grade gliomas (18/41; 44%) were assigned a score of 2 when analyzing the MAP2 immunolabeling percentage, followed by 3 (16/41; 39%), and 1 (7/41; 17%). This evidence concerns the gene MAP2 and neoplasm.